Safety of AS03-adjuvanted split-virion H1N1 (2009) pandemic influenza vaccine: a prospective cohort study

Irwin Nazareth, Fernanda Tavares, Dominique Rosillon, François Haguinet, Vincent Bauchau, Irwin Nazareth, Fernanda Tavares, Dominique Rosillon, François Haguinet, Vincent Bauchau

Abstract

Objectives: To assess the safety of an AS03-adjuvanted split virion H1N1 (2009) vaccine (Pandemrix) in persons vaccinated during the national pandemic influenza vaccination campaign in the UK.

Design: Prospective, cohort, observational, postauthorisation safety study.

Setting: 87 general practices forming part of the Medical Research Council General Practice Research Framework and widely distributed throughout England.

Participants: A cohort of 9143 individuals aged 7 months to 97 years who received at least one dose of the AS03-adjuvanted H1N1 pandemic vaccine during the national pandemic influenza vaccination campaign in the UK was enrolled. 94% completed the 6-month follow-up. Exclusion criteria were previous vaccination with other H1N1 pandemic vaccine and any child in care.

Primary and secondary outcome measures: Medically attended adverse events (MAEs) occurring within 31 days after any dose, serious adverse events (SAEs) and adverse events of special interest (AESIs) following vaccination were collected for all participants. Solicited adverse events (AEs) were assessed in a subset of participants.

Results: MAEs were reported in 1219 participants and SAEs in 113 participants during the 31-day postvaccination period. The most frequently reported MAEs and SAEs were consistent with events expected to be reported during the winter season in this population: lower respiratory tract infections, asthma and pneumonia. The most commonly reported solicited AEs were irritability in young children aged <5 years (61.8%), muscle aches in children aged 5-17 years (61.9%) and adults (46.9%). 18 AESIs, experienced by 14 patients, met the criteria to be considered for the observed-to-expected analyses. AESIs above the expected number were neuritis (1 case within 31 days) and convulsions (8 cases within 181 days). There were 41 deaths during the 181-day period after vaccination, fewer than expected.

Conclusions: Results indicate that the AS03-adjuvanted H1N1 pandemic vaccine showed a clinically acceptable reactogenicity and safety profile in all age and risk groups studied.

Trial registration: ClinicalTrials.gov, NCT00996853.

Figures

Figure 1
Figure 1
Flow diagram depicting the completion of study contact points with the reasons for discontinuation. Participants with contacts not performed for other reasons could have had the following contacts. If only one dose of vaccine was given, Contact 2 was considered ‘Missing confirmed’.
Figure 2
Figure 2
Solicited local (A) and general (B) adverse events reported during a 7-day follow-up period after any dose (Reactogenicity cohort N=682). The general symptoms of drowsiness, irritability and loss of appetite were only assessed in children

References

    1. Centers for Diseaes Control and Prevention (CDC) Update: novel influenza A (H1N1) virus infections—worldwide, May 6, 2009. MMWR Morb Mortal Wkly Rep 2009;58:453–8
    1. Centers for Disease Control and Prevention (CDC) Outbreak of swine-origin influenza A (H1N1) virus infection—Mexico, March-April 2009. MMWR Morb Mortal Wkly Rep 2009;58:467–70
    1. Centers for Disease Control and Prevention (CDC) Swine influenza A (H1N1) infection in two children—southern California, March-April 2009. MMWR Morb Mortal Wkly Rep 2009;58:400–2
    1. European Centre for Disease Prevention and Control ECDC Interim Guidance. Use of specific pandemic influenza vaccines during the H1N1 2009 pandemic. Aug 2009. European Centre for Disease Prevention and Control website. (accessed 13 Apr 2012)
    1. National Center for Immunization and Respiratory Diseases (CDC), Centers for Disease Control and Prevention (CDC) Use of influenza A (H1N1) 2009 monovalent vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recomm Rep 2009;58:1–8
    1. GlaxoSmithKline UK Pandemrix suspension and emulsion for emulsion for injection. Summary of product characteristics. 17 Jan 2012. The electronic Medicinces Compendium (eMC) website. (accessed 13 Apr 2012)
    1. Roman F, Vaman T, Gerlach B, et al. Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial. Vaccine 2010;28:1740–5
    1. Leroux-Roels I, Borkowski A, Vanwolleghem T, et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 2007;370:580–9
    1. Rumke HC, Bayas JM, de Juanes JR, et al. Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trial. Vaccine 2008;26:2378–88
    1. European Medicines Agency CHMP recommendations for the pharmacovigilance plan as part of the risk management plan to be submitted with the marketing authorisation application for a pandemic influenza vaccine. 24 Sep 2009.European Medicines Agency website. (accessed 13 Apr 2012)
    1. UK Department of Health H1N1 swine flu vaccination programme. 26 Jun 2009. UK Department of Health website. (accessed 13 Apr 2012)
    1. UK Department of Health A (H1N1) swine influenza: vaccination programme update. 15 Oct 2009. UK Department of Health website. (accessed 13 Apr 2012)
    1. Donaldson L, Beasley C, Ridge K. The influenza immunisation programme 2009/10. 3 Apr 2009. UK Department of Health website. (accessed 13 Apr 2012)
    1. Tavares F, Nazareth I, Monegal JS, et al. Pregnancy and safety outcomes in women vaccinated with an AS03-adjuvanted split virion H1N1 (2009) pandemic influenza vaccine during pregnancy: a prospective cohort study. Vaccine 2011;29:6358–65
    1. Olafsson E, Ludvigsson P, Gudmundsson G, et al. Incidence of unprovoked seizures and epilepsy in Iceland and assessment of the epilepsy syndrome classification: a prospective study. Lancet Neurol 2005;4:627–34
    1. Soderstrom M. The clinical and paraclinical profile of optic neuritis: a prospective study. Ital J Neurol Sci 1995;16:167–76
    1. Rowlands S, Hooper R, Hughes R, et al. The epidemiology and treatment of Bell's palsy in the UK. Eur J Neurol 2002;9:63–7
    1. Hughes RA, Charlton J, Latinovic R, et al. No association between immunization and Guillain-Barre syndrome in the United Kingdom, 1992 to 2000. Arch Intern Med 2006;166:1301–4
    1. Modrego PJ, Pina MA. Trends in prevalence and incidence of multiple sclerosis in Bajo Aragon, Spain. J Neurol Sci 2003;216:89–93
    1. Office for National Statistics Mortality statistics: deaths registered in England and Wales (Series DR), 2007. Office of National Statistics website. (accessed 13 Apr 2012)
    1. Mackenzie I, Macdonald T, Shakir S, et al. Influenza H1N1 (swine flu) vaccination: a safety surveillance feasibility study using self-reporting of serious adverse events and pregnancy outcomes. Br J Clin Pharmacol 2012;73:801–11
    1. Madhun AS, Akselsen PE, Sjursen H, et al. An adjuvanted pandemic influenza H1N1 vaccine provides early and long term protection in health care workers. Vaccine 2010;29:266–73
    1. Nicholson KG, Abrams KR, Batham S, et al. Immunogenicity and safety of a two-dose schedule of whole-virion and AS03A-adjuvanted 2009 influenza A (H1N1) vaccines: a randomised, multicentre, age-stratified, head-to-head trial. Lancet Infect Dis 2011;11:91–101
    1. Roman F, Vaman T, Kafeja F, et al. AS03(A)-Adjuvanted influenza A (H1N1) 2009 vaccine for adults up to 85 years of age. Clin Infect Dis 2010;51:668–77
    1. Garcia-Sicilia J, Gillard P, Carmona A, et al. Immunogenicity and safety of AS03-adjuvanted H1N1 pandemic vaccines in children and adolescents. Vaccine 2011;29:4353–61
    1. Carmona A, Omenaca F, Tejedor JC, et al. Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6–35 months. Vaccine 2010;28:5837–44
    1. Diez-Domingo J, Garces-Sanchez M, Baldo JM, et al. Immunogenicity and safety of H5N1 A/Vietnam/1194/2004 (Clade 1) AS03-adjuvanted prepandemic candidate influenza vaccines in children aged 3 to 9 years: a phase ii, randomized, open, controlled study. Pediatr Infect Dis J 2010;29:e35–46
    1. Chief Medical Officer Advice Continued temporary suspension of use of seasonal influenza vaccine in children aged 5 years of age and under. 23 Apr 2010. Australian Government Department of Health and Ageing, Immunise Australia Program website. (accessed 13 Apr 2012)
    1. Armstrong PK, Dowse GK, Effler PV, et al. Epidemiological study of severe febrile reactions in young children in Western Australia caused by a 2010 trivalent inactivated influenza vaccine. BMJ Open 2011;1 (accessed 13 Apr 2012)
    1. Stowe J, Andrews N, Bryan P, et al. Risk of convulsions in children after monovalent H1N1 (2009) and trivalent influenza vaccines: a database study. Vaccine 2011;29:9467–72
    1. Schonberger LB, Bregman DJ, Sullivan-Bolyai JZ, et al. Guillain-Barre syndrome following vaccination In The National Influenza Immunization Program, United States, 1976–1977. Am J Epidemiol 1979;110:105–23
    1. Hurwitz ES, Schonberger LB, Nelson DB, et al. Guillain-Barré Syndrome and the 1978–1979 Influenza Vaccine. N Engl J Med 1981;304:1557–61
    1. Kaplan JE, Katona P, Hurwitz ES, et al. Guillain-Barré Syndrome in the United States, 1979–1980 and 1980–1981. Lack of an association with influenza vaccination. JAMA 1982;248:698–700
    1. Yin JK, Khandaker G, Rashid H, et al. Immunogenicity and safety of pandemic influenza A (H1N1) 2009 vaccine: systematic review and meta-analysis. Influenza Other Respir Viruses 2011;5:299–305
    1. Centers for Disease Control and Prevention (CDC) Preliminary results: surveillance for Guillain-Barre syndrome after receipt of influenza A (H1N1) 2009 monovalent vaccine—United States, 2009–2010. MMWR Morb Mortal Wkly Rep 2010;59:657–61
    1. Dieleman J, Romio S, Johansen K, et al. Guillain-Barre syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccine: multinational case-control study in Europe. BMJ 2011;343:d3908.
    1. Grimaldi-Bensouda L, Alperovitch A, Besson G, et al. Guillain-Barre syndrome, influenzalike illnesses, and influenza vaccination during seasons with and without circulating A/H1N1 viruses. Am J Epidemiol 2011;174:326–35
    1. Confavreux C, Suissa S, Saddier P, et al. Vaccinations and the risk of relapse in multiple sclerosis. Vaccines in Multiple Sclerosis Study Group. N Engl J Med 2001;344:319–26
    1. Miller AE, Morgante LA, Buchwald LY, et al. A multicenter, randomized, double-blind, placebo-controlled trial of influenza immunization in multiple sclerosis. Neurology 1997;48:312–14
    1. Mokhtarian F, Shirazian D, Morgante L, et al. Influenza virus vaccination of patients with multiple sclerosis. Mult Scler 1997;3:243–7
    1. Salvetti M, Pisani A, Bastianello S, et al. Clinical and MRI assessment of disease activity in patients with multiple sclerosis after influenza vaccination. J Neurol 1995;242:143–6

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir